ArticleJournal of medicinal chemistry2022
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery.Medicinal research reviews · 2026Review
- An HDAC4-specific PROTAC degrader achieves radiation sensitization by enhancing ferroptosis in lung cancer.Nature communications · 2026Article
- The Future of Epigenetics: Emerging Technologies and Clinical Applications.ACS pharmacology & translational science · 2026Review
- Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer.Molecular oncology · 2026Article
- Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies.Biomolecules · 2026Review
- Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment.Future medicinal chemistry · 2025Review
- Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function.Acta pharmaceutica Sinica. B · 2025Article
- Inhibition of class IIa HDACs reduces mutant HTT aggregation by affecting RNA stability.Frontiers in molecular neuroscience · 2025Article
- Review
- The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Unlocking the epigenetic symphony: histone acetylation's impact on neurobehavioral change in neurodegenerative disorders.Epigenomics · 2024Review
- Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.Acta pharmaceutica Sinica. B · 2024Review
- Degraders in epigenetic therapy: PROTACs and beyond.Theranostics · 2024Review
- Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management.Current neuropharmacology · 2024Review
- Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- PROTAC chemical probes for histone deacetylase enzymes.RSC chemical biology · 2023Review
- Transcriptome analysis identifies the role of Class I histone deacetylase in Alzheimer's disease.Heliyon · 2023Article
- Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.Life medicine · 2023Review
- Room Temperature Synthesis of Bioactive 1,2,4-Oxadiazoles.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 2 institutions in 3 countries.
Natsuko MacabuagDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
William EsmieuDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Perla BrecciaDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.ORCID 0000-0002-8552-9012
Rebecca JarvisDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Wesley BlackabyDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Ovadia LazariDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Liudvikas UrbonasDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Maria EznarriagaDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Rachel WilliamsDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Annelieke StrijboschCharles River, Darwinweg 24, Leiden 2333 CR, The Netherlands.
Rhea Van de BospoortCharles River, Darwinweg 24, Leiden 2333 CR, The Netherlands.
Kim MatthewsDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Cole ClissoldDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Tammy LadduwahettyDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.
Huw VaterDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, U.K.ORCID 0000-0002-2904-1848
Patrick HeaphyCuria, The Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States.
Douglas G StaffordCuria, The Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States.
Hong-Jun WangCuria, The Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States.
John E MangetteCuria, The Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States.
George McAllisterCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Vahri BeaumontCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Thomas F VogtCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Hilary A WilkinsonCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Elizabeth M DohertyCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Celia DominguezCHDI Management/CHDI Foundation, 6080 Center Drive, Los Angeles, California 90045, United States.
Charles River Laboratories (Netherlands) · NLCHDI Foundation · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a lethal autosomal dominant neurodegenerative disorder resulting from a CAG repeat expansion in the huntingtin (
Indexed as
Histone DeacetylasesHuntington DiseaseAnimalsDisease Models, AnimalDrug DevelopmentHuntingtin ProteinMiceNeuronsProteolysisUbiquitinsHdac5 protein, mouseHistone DeacetylasesHuntingtin ProteinUbiquitins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.